<DOC>
	<DOCNO>NCT00006380</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Phase I trial study effectiveness monoclonal antibody therapy treat patient prostate cancer longer respond antiandrogen therapy .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine biodistribution normal organ dosimetry iodine I 131 monoclonal antibody muJ591 patient progressive androgen independent prostate cancer . II . Determine safety drug patient . III . Determine pharmacokinetics drug patient . IV . Determine human antimouse antibody response patient drug . V. Determine antitumor effect drug patient . OUTLINE : This dose escalation study iodine I 131 monoclonal antibody muJ591 ( 131I-J591 ) . Patients receive unlabeled monoclonal antibody muJ591 IV 1 hour follow 131I-J591 IV 1 hour . Cohorts 3-6 patient receive escalate dos 131I-J591 ( radioactivity escalate , monoclonal antibody dose fix ) maximum tolerate dose ( MTD ) determine . The MTD define dose 2 3 6 patient experience dose limit toxicity . Patients follow week 3 , 4 , 6 , 8 , 9 , 12 , every 6 month month 21 . PROJECTED ACCRUAL : A total 3-24 patient accrue study 12 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm androgen independent prostate cancer progress castrate level testosterone Progression document one follow way : A minimum 3 rise PSA value baseline obtain 1 week apart 2 measurement 2 week apart New osseous lesion bone scan Greater 25 % increase bidimensionally measurable soft tissue disease , appearance new site disease Patients antiandrogen must show progression antiandrogen prior study Testosterone great 50 ng/mL No residual proctitis follow radiotherapy No active CNS epidural primary tumor metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : WBC great 3,500/mm3 Hemoglobin great 10 g/dL Platelet count great 150,000/mm3 Hepatic : Bilirubin le 1.5 mg/dL GGT le upper limit normal ( ULN ) AST le ULN PT le 14 second No autoimmune hepatitis Renal : Creatinine le 1.5 mg/dL OR Creatinine clearance great 60 mL/min Cardiovascular : No New York Heart Association class III IV cardiac disease Pulmonary : No severe debilitate pulmonary disease Other : No active uncontrolled infection infection require IV antibiotic treatment No evidence human antimouse antibody No prior autoimmune disease No prior GI hemorrhage HIV negative Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 2 month since prior pack red blood cell transfusion No prior murine human antibody therapy No prior murine protein No concurrent immunotherapy Chemotherapy : At least 4 week since prior chemotherapy recover No concurrent chemotherapy Endocrine therapy : See Disease Characteristics Concurrent gonadotropin release hormone analog require patient undergone surgical orchiectomy No concurrent hormonal therapy Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy recover No prior diagnostic scintigram ( e.g. , ProstaScint , Myoscint , Oncoscint ) No prior radiotherapy sternum alone OR No primary radiotherapy prostate one site OR No prior radiotherapy 25 % skeleton No prior treatment strontium chloride Sr 89 Samarium Sm 153 lexidronam pentasodium No concurrent radiotherapy localize site ( e.g. , bone ) use indicator lesion Surgery : No concurrent surgery sole site measurable disease Other : At least 4 week since investigational anticancer therapeutic drug recover No concurrent aspirin , nonsteroidal antiinflammitory agent , anticoagulant , drug may induce exacerbate bleeding tendency</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>